Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers
Determine the pharmacokinetic interactions between rapamycin and sunitinib in patients with advanced solid tumors.
Solid Tumors
DRUG: sunitinib|DRUG: rapamycin
Pharmacokinetic interactions, 4 weeks
Toxicity of the combined drug regimen, 4 weeks|Response to drug regimen, 8 weeks
Determine the pharmacokinetic interactions between rapamycin and sunitinib in patients with advanced solid tumors.